From market research to funding, today, we will dismantle the top 5 reasons for startup failure. At HEMEX, we have seen many cases in our years of experience in this field. For this reason, we hope to give you some hints to look out for while navigating the ever-changing startup ecosystem.
Increasing patients’ safety and care in research is vital when preparing and conducting your study. From a HEMEX perspective, we are tackling in this article four important points you should consider during the process.
Eating healthier, regular exercise, or reading more books – many people use the New Year to tackle new projects or follow through on old plans. What’s on your list of New Year’s resolutions for 2022?
The Austrian biotech company is developing endolysins and phages as therapeutics, focusing on persistent bacterial infections that cannot be targeted with broad-spectrum antibiotics. This acquisition is a big step for the AMR crisis and the formerly Phagomed team. At HEMEX, we wanted to congratulate them on their fantastic job!
Complicated words and sentences may be misunderstood and are very often unfamiliar to the patients. This led us to discuss how we could find the optimal solution for all parties involved in a clinical study: the patient, physician, and sponsor/CRO.
Every Start-up knows the importance of a great pitch. Today we want to give you some advice on how to find out the essential ingredients to bake a delicious pitch which investors will enjoy every single bite. More importantly, leave them craving for more!
Inura Medical’s mission is to improve women’s health through the development of an urethral ovulum for the treatment of patients suffering from urinary bladder diseases. Their first pharmaceutical product is addressing an unmet medical need in overactive bladder (OAB).
HexagonFab, a spin-out from the University of Cambridge, has developed a novel approach for drug discovery and production process monitoring called the Bolt. This innovative device is an analytical lab instrument that provides convenient and affordable access to molecular binding analytics.